» Articles » PMID: 30195775

Ribosomal Protein S3 Gene Silencing Protects Against Cigarette Smoke-Induced Acute Lung Injury

Overview
Publisher Cell Press
Date 2018 Sep 10
PMID 30195775
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic obstructive pulmonary disease (COPD) is estimated to be the third leading cause of death by 2030. Transcription factor NF-κB may play a critical role in COPD pathogenesis. Ribosomal protein S3 (RPS3), a 40S ribosomal protein essential for executing protein translation, has recently been found to interact with the NF-κB p65 subunit and promote p65 DNA-binding activity. We sought to study whether RPS3 gene silencing could protect against cigarette-smoke (CS)-induced acute lung injury in a mouse model. Effects of an intratracheal RPS3 siRNA in CS-induced lung injury were determined by measuring bronchoalveolar lavage (BAL) fluid cell counts, levels of inflammatory and oxidative damage markers, and NF-κB translocation. Lung RPS3 level was found to be upregulated for the first time with CS exposure, and RPS3 siRNA blocked CS-induced neutrophil counts in BAL fluid. RPS3 siRNA suppressed CS-induced lung inflammatory mediator and oxidative damage marker levels, as well as nuclear p65 accumulation and transcriptional activation. RPS3 siRNA was able to disrupt CS extract (CSE)-induced NF-κB activation in an NF-κB reporter gene assay. We report for the first time that RPS3 gene silencing ameliorated CS-induced acute lung injury, probably via interruption of the NF-κB activity, postulating that RPS3 is a novel therapeutic target for COPD.

Citing Articles

L. significantly alleviates cigarette smoke-induced acute lung injury by lowering NF-κB pathway activation and inflammatory mediators.

Hussain N, Ikram N, Khan K, Hussain L, Alqahtani A, Alqahtani T Heliyon. 2023; 9(11):e22055.

PMID: 38045213 PMC: 10692792. DOI: 10.1016/j.heliyon.2023.e22055.


Applications and advancements of nanoparticle-based drug delivery in alleviating lung cancer and chronic obstructive pulmonary disease.

De Rubis G, Paudel K, Corrie L, Mehndiratta S, Patel V, Kumbhar P Naunyn Schmiedebergs Arch Pharmacol. 2023; 397(5):2793-2833.

PMID: 37991539 DOI: 10.1007/s00210-023-02830-w.


Differential expression profile of plasma exosomal microRNAs in acute type A aortic dissection with acute lung injury.

Zhang C, Bai H, Zhang L, Zhang Y, Chen X, Shi R Sci Rep. 2022; 12(1):11667.

PMID: 35804020 PMC: 9270349. DOI: 10.1038/s41598-022-15859-3.


Inhaled siRNA Formulations for Respiratory Diseases: From Basic Research to Clinical Application.

Fan Y, Yang Z Pharmaceutics. 2022; 14(6).

PMID: 35745766 PMC: 9227582. DOI: 10.3390/pharmaceutics14061193.


STAT3-activated lncRNA XIST accelerates the inflammatory response and apoptosis of LPS-induced acute lung injury.

Li J, Xue L, Wu Y, Yang Q, Liu D, Yu C J Cell Mol Med. 2021; 25(14):6550-6557.

PMID: 34114724 PMC: 8278113. DOI: 10.1111/jcmm.16653.


References
1.
Vlahos R, Bozinovski S, Jones J, Powell J, Gras J, Lilja A . Differential protease, innate immunity, and NF-kappaB induction profiles during lung inflammation induced by subchronic cigarette smoke exposure in mice. Am J Physiol Lung Cell Mol Physiol. 2005; 290(5):L931-45. DOI: 10.1152/ajplung.00201.2005. View

2.
Vernooy J, Lindeman J, Jacobs J, Hanemaaijer R, Wouters E . Increased activity of matrix metalloproteinase-8 and matrix metalloproteinase-9 in induced sputum from patients with COPD. Chest. 2004; 126(6):1802-10. DOI: 10.1378/chest.126.6.1802. View

3.
Owen C . Roles for proteinases in the pathogenesis of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2008; 3(2):253-68. PMC: 2629972. DOI: 10.2147/copd.s2089. View

4.
Durcan N, Murphy C, Cryan S . Inhalable siRNA: potential as a therapeutic agent in the lungs. Mol Pharm. 2008; 5(4):559-66. DOI: 10.1021/mp070048k. View

5.
Kole R, Krainer A, Altman S . RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov. 2012; 11(2):125-40. PMC: 4743652. DOI: 10.1038/nrd3625. View